印度治疗药物监测的SWOT分析
该综述对印度治疗药物监测(TDM)进行优势、劣势、机会与威胁(SWOT)分析,指出TDM实践仅限少数学术医疗中心和教学医院,除免疫抑制剂外,抗癌药、抗真菌药、抗生素和抗结核药等领域有改善患者结局的潜力。文章呼吁建立包含TDM专业人员、临床医生和政府的合作组,制定国家行动计划以加强TDM。
要点
- 印度TDM实践不广泛,目前仅限于少数学术医疗中心和教学医院。
- 除免疫抑制剂外,抗癌、抗真菌、抗生素和抗结核等治疗领域有改善患者结局的潜力。
- 需建立合作组和国家行动计划,设立节点TDM中心并开展试点项目。
核心结论
- 印度TDM未能获得应有重视,需采取适当措施促进其发展。
- 需要建立包含所有利益相关者的合作组并制定国家行动计划以加强TDM。
研究设计与样本
- 本文为综述,对印度TDM进行SWOT分析。
主要发现
- 过去三到四十年,TDM已发展为治疗药物管理,是精准医学的组成部分。
- 印度TDM实践不广泛,目前仅限于少数学术医疗中心和教学医院。
- 除免疫抑制剂外,抗癌、抗真菌、抗生素和抗结核等治疗领域在印度环境下有改善患者结局的巨大潜力。
- 营养缺乏患病率较高、热带疾病、替代药物广泛使用、药物基因组学不同以及人群特异性治疗范围数据稀少等因素使印度次大陆人群在TDM相关性方面独特。
临床怎么用
- 应建立节点TDM中心并开展试点项目以确定该国TDM重点领域。
- 应进行能力建设并提高认识,将TDM纳入主流临床医学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the last three to four decades, Therapeutic Drug Monitoring (TDM) has shaped itself as therapeutic drug management, an integral component of precision medicine. The practice of TDM is not extensive in India, despite being one of the fastest-growing economies in the world. It is currently limited to a few academic medical centres and teaching hospitals. Apart from the immunosuppressive drugs, several other therapeutic areas, such as anticancer, antifungal, antibiotic and antitubercular, have demonstrated great potential to improve patient outcomes in Indian settings. Factors such as the higher prevalence of nutritional deficiencies, tropical diseases, widespread use of alternative medicines, unalike pharmacogenomics and sparse population-specific data available on therapeutic ranges of several drugs make the population of this subcontinent unique regarding the relevance of TDM. Despite the impact of TDM in clinical science and its widespread application, TDM has failed to receive the attention it deserves in India. This review intends to bring out a strength, weakness, opportunity and threats (SWOT) analysis for TDM in India so that appropriate steps for fostering the growth of TDM could be envisioned. The need of the hour is the creation of a cooperative group including all the stakeholders, such as TDM professionals, clinicians and the government and devising a National Action Plan to strengthen TDM. Nodal TDM centres should be established, and pilot programmes should be rolled out to identify the thrust areas for TDM in the country, capacity building and creating awareness to integrate TDM into mainstream clinical medicine.
引用
- Pattanaik S, Gota V, Tripathi SK, et al. Therapeutic drug monitoring in India: A strength, weakness, opportunity and threats analysis. Br J Clin Pharmacol. 2023. PMID: 37259249. doi:10.1111/bcp.15808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。